xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05993520</url>
    </required_header>
    <id_info>
      <org_study_id>GAslan-2023</org_study_id>
      <nct_id>NCT05993520</nct_id>
    </id_info>
    <brief_title>Effects of Respiratory Muscle Functions on Interstitial Lung Disease: Sleep Quality, Dyspnea, and Fatigue</brief_title>
    <official_title>Effects of Respiratory Muscle Functions on Interstitial Lung Disease: Sleep Quality, Dyspnea, and Fatigue</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Istanbul University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>TURK TORAKS DERNEGI</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Istanbul University</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Although there are numerous data demonstrating the impact of Interstitial Lung Disease (ILD)&#xD;
        on respiratory functions, there is a lack of studies investigating the effects of respiratory&#xD;
        functions on parameters such as sleep quality, dyspnea, and fatigue. The primary objective of&#xD;
        the study is to examine the influence of changes in respiratory muscle functions in ILD on&#xD;
        sleep quality, dyspnea, and fatigue parameters. The secondary objective is to investigate the&#xD;
        effects of respiratory muscle functions in ILD on parameters such as cough, pain, exercise&#xD;
        capacity, peripheral muscle strength, anxiety, depression, and quality of life.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Introduction: Despite having numerous data demonstrating the impact of Interstitial Airway&#xD;
        Disease (IAD) on respiratory functions, there is a lack of studies investigating the effects&#xD;
        of respiratory functions on parameters such as sleep quality, dyspnea, and fatigue. The&#xD;
        primary objective of the study is to examine the effects of changes in respiratory muscle&#xD;
        functions in IAD on sleep quality, dyspnea, and fatigue parameters. The secondary objective&#xD;
        is to investigate the effects of respiratory muscle functions in IAD on parameters such as&#xD;
        cough, pain, exercise capacity, peripheral muscle strength, anxiety, depression, and quality&#xD;
        of life.&#xD;
  &#xD;
        Methods: Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who&#xD;
        were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul&#xD;
        Faculty of Medicine, and met the inclusion criteria, were included in the project.&#xD;
        Participants' respiratory function tests, respiratory muscle functions, dyspnea levels,&#xD;
        cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and&#xD;
        fatigue levels were evaluated. Pearson Correlation Test was applied to determine the&#xD;
        relationship between variables. Multiple linear regression analysis was used to examine&#xD;
        factors that could affect respiratory muscle strength and endurance values.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Completed</overall_status>
    <start_date type="Actual">June 1, 2020</start_date>
    <completion_date type="Actual">June 1, 2023</completion_date>
    <primary_completion_date type="Actual">May 1, 2023</primary_completion_date>
    <study_type>Observational [Patient Registry]</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Case-Only</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <target_duration>1 Day</target_duration>
    <primary_outcome>
      <measure>sleep quality-1</measure>
      <time_frame>5 minutes</time_frame>
      <description>Pittsburgh Sleep Quality Index (PSQI) will be used to assess sleep quality. PSQI is a scale consisting of 24 questions that evaluate sleep quality and disturbances in the past month. Each item is scored between 0 and 3, and a total score higher than 5 indicates insufficient sleep quality in the individual.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Sleep Apnea</measure>
      <time_frame>5 minutes</time_frame>
      <description>Obstructive Sleep Apnea Syndrome Risk: The STOP-BANG questionnaire will be used to assess the risk of Obstructive Sleep Apnea Syndrome (OSAS). The questionnaire consists of a total of eight questions that are answered with &quot;yes&quot; or &quot;no.&quot; In the STOP section of the questionnaire, if at least two out of the four questions are answered &quot;yes,&quot; it is considered a high risk for OSAS.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Modified Medical Research Council Questionnaire</measure>
      <time_frame>5 minutes</time_frame>
      <description>To assess dyspnea, the Modified Medical Research Council (mMRC) Questionnaire will be used.&#xD;
  The mMRC is a scale used to assess the level of dyspnea during daily life activities. It involves a five-point category scale (0 to 4) in which patients choose the expression that best describes their level of dyspnea. As the score increases, the severity of dyspnea also increases.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Dyspnea-12 Scale</measure>
      <time_frame>5 minutes</time_frame>
      <description>To assess dyspnea, the Dyspnea-12 Scale will be used.&#xD;
  The Dyspnea-12 Scale is a 12-item questionnaire that measures the intensity of dyspnea. It consists of a four-point Likert-type scale (0=none, 1=mild, 2=moderate, 3=severe) as response options.The minimum score is 0, and the maximum score is 36. An increase in the score indicates an increase in the severity of dyspnea experienced by the patient.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>fatigue</measure>
      <time_frame>5 minutes</time_frame>
      <description>For the assessment of fatigue, the Fatigue Assessment Scale (FAS) will be used. The FAS is a subjective fatigue questionnaire consisting of 10 items. It utilizes a five-point Likert scale (1=Always-5=Never) as response options. The total scores that can be obtained from the FAS range from 10 to 50. Higher scores indicate a higher level of fatigue experienced by the individual.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Respiratory Function Test</measure>
      <time_frame>5 minutes</time_frame>
      <description>Respiratory Function Test: The respiratory function status of patients will be assessed using spirometric testing.Spirometry is a medical test used to assess the functioning of the lungs. It measures the amount of air a person can inhale and exhale, as well as the speed and volume of airflow. This test is essential for diagnosing and monitoring lung conditions such as interstitial lung disease, chronic obstructive pulmonary disease (COPD), and other respiratory disorders.The spirometry results are compared to predicted values based on factors such as age, height, sex, and ethnicity. This comparison helps healthcare professionals identify any deviations from normal lung function.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Respiratory Muscle Strength</measure>
      <time_frame>5 minutes</time_frame>
      <description>Respiratory Muscle Strength: The easiest and most common method is measuring mouth pressure during voluntary contraction against a closed airway to open the airway. In the study, respiratory muscle strength will be evaluated using the &quot;Vyaire Medical MicroRPM&quot; device. Maximum Inspiratory Pressure (MIP): At least three measurements are taken, and the highest value is recorded. Maximum Expiratory Pressure (MEP): The best of at least three measurements is recorded.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Comorbidity</measure>
      <time_frame>3 minutes</time_frame>
      <description>Charlson Comorbidity Index: It is a widely used index in clinical practice that queries chronic systemic diseases, assesses their frequency and relationships. It consists of nineteen different items. The scores obtained from the patient's comorbid conditions are added together to obtain a score, and a score is also added based on the patient's age. This age score is 1 for ages 50-59, 2 for ages 60-69, 3 for ages 70-79, 4 for ages 80-89, and 5 for ages 90-99.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Respiratory Muscle Endurance:</measure>
      <time_frame>8 minutes</time_frame>
      <description>Respiratory Muscle Endurance: In respiratory muscle endurance measurement, an incremental threshold load test will be applied using the &quot;Threshold IMT&quot; device. According to the incremental threshold load protocol, after determining the MIP value, the threshold pressure is set at approximately 20-40% of MIP. The threshold pressure is increased every two minutes. The highest pressure that the patient can sustain for at least one minute is recorded as the patient's respiratory muscle endurance value.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Cough</measure>
      <time_frame>5 minutes</time_frame>
      <description>Leicester Cough Questionnaire will be used for the assessment of cough. It consists of 19 items with a 7 point likert response scale (range from 1 to 7).Each item is developed to assess symptoms during cough and impact of cough on three main domains: physical, psychological and social. Scores are calculated as a mean of each domain and the total score is calculated by adding every domain score. The total severity score ranges 3-21, with a lower score indicating greater impairment of health status due to cough.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Symptoms Seveerity</measure>
      <time_frame>1 minutes</time_frame>
      <description>Dispnea, Pain, and Cough Severity: Dispnea, pain, and cough severity will be assessed using the Visual Analog Scale (VAS). VAS is used to convert some values that cannot be measured numerically into numerical form. It involves a 100 mm line with the two endpoints representing the two extreme definitions of the parameter to be evaluated (e.g., no pain/cough - very severe pain/cough). The patient is asked to indicate their own condition by drawing a line, placing a dot, or marking a point on this line to indicate where their situation corresponds. The point marked by the patient is measured using a ruler. The resulting number represents the patient's level of pain/cough severity.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>exercise capacity</measure>
      <time_frame>8 minutes</time_frame>
      <description>The Six-Minute Walk Test (6MWT) will be used to assess exercise capacity. The 6MWT determines individuals' submaximal functional exercise capacity. The patient will be asked to walk as far as possible at their own walking pace for six minutes in a straight 30-meter corridor. Before starting the test, the patient rests in a sitting position in the corridor for 10 minutes. Prior to the test, oxygen saturation, heart rate, blood pressure, dyspnea, and leg fatigue scores are recorded using the Modified Borg Scale. If the patient wants to rest during the test, the resting time is included in the test duration without stopping the stopwatch. At the end of the test, the assessments made before the test are repeated. The distance walked in six minutes (6MWD) is recorded in meters.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>peripheral muscle strength</measure>
      <time_frame>5 minutes</time_frame>
      <description>The &quot;J-Tech CommanderTM Muscle Tester&quot; hand-held dynamometer will be used to assess the strength of the quadriceps femoris muscle. The hand-held dynamometer is a simple, easy-to-use, portable, time-efficient, inexpensive, and lightweight device that measures maximum isometric muscle strength.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>anxiety&amp;depression</measure>
      <time_frame>5 minutes</time_frame>
      <description>The Hospital Anxiety and Depression Scale (HADS) will be used to determine the anxiety and depression status. HADS is a self-report questionnaire developed to assess the risk, level, and severity of anxiety and depression in individuals with physical illnesses and those seeking primary healthcare services. It consists of a total of 14 questions, with seven questions (odd numbers) measuring anxiety and the other seven questions (even numbers) measuring depression. It is a four-point Likert-type scale. The cutoff score for the anxiety subscale (HADS-A) is 10/11, and for the depression subscale (HADS-D) is 7/8.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>health problems</measure>
      <time_frame>5 minutes</time_frame>
      <description>The Nottingham Health Profile (NHP) was originally created as a standardised tool to survey health problems and measure medical or social interventions. The NHP is a patient-reported questionnaire. Respondents tick yes or no boxes to answer questions about their health and its effects on their daily life.&#xD;
  The questionnaire is divided into two parts. The first parts comprises 38 questions in six categories: sleep, physical mobility, energy, pain, emotional reactions, and social isolation. This first section is weighted to reflect how severe an impact the respondent thinks their health is having on the above areas of life. The second part of the NHP is made up of seven statements about areas of life that are commonly affected by health: paid employment, jobs around the house, social life, personal relationships, sex life, hobbies and interests, and holidays. Scores on the NHP can range from 0 i.e. no distress to 100 i.e severe distress.</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Actual">36</enrollment>
    <condition>Interstitial Lung Disease</condition>
    <arm_group>
      <arm_group_label>Interstitial Lung Disease</arm_group_label>
      <description>Between June 2020 and June 2023, a total of 36 voluntary participants, aged 18 and above, who were receiving treatment at the Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, and met the inclusion criteria, were included in the study.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Assessment</intervention_name>
      <description>Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.</description>
      <arm_group_label>Interstitial Lung Disease</arm_group_label>
    </intervention>
    <eligibility>
      <study_pop>
        <textblock>
          Between June 2020 and June 2023, a total of 36 voluntary participants, aged 18 and above,&#xD;
          who were receiving treatment at the Department of Chest Diseases, Istanbul Faculty of&#xD;
          Medicine, Istanbul University, and met the inclusion criteria were included in the study.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Being 18 years of age or older.&#xD;
  &#xD;
            -  Having a diagnosis of Interstitial Lung Disease (ILD) by a chest diseases specialist.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Systemic involvement of ILD&#xD;
  &#xD;
            -  Cooperation problem&#xD;
  &#xD;
            -  Presence of orthopedic/neurological issues hindering walking and exercise.&#xD;
  &#xD;
            -  Uncontrolled cardiovascular disease.&#xD;
  &#xD;
            -  Presence of acute upper and lower respiratory tract infections.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>70 Years</maximum_age>
    </eligibility>
    <location>
      <facility>
        <name>İstanbul Üniversitesi-Cerrahpaşa</name>
        <address>
          <city>Istanbul</city>
          <state>Buyucekmece</state>
          <country>Turkey</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Turkey</country>
    </location_countries>
    <results_reference>
      <citation>Bloem AEM, Houben-Wilke S, Mostard RLM, Stoot N, Janssen DJA, Franssen FME, Custers JWH, Spruit MA. Respiratory and non-respiratory symptoms in patients with IPF or sarcoidosis and controls. Heart Lung. 2023 Sep-Oct;61:136-146. doi: 10.1016/j.hrtlng.2023.05.013. Epub 2023 Jun 2.</citation>
      <PMID>37269615</PMID>
    </results_reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>July 21, 2023</study_first_submitted>
    <study_first_submitted_qc>August 14, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 15, 2023</study_first_posted>
    <last_update_submitted>August 15, 2023</last_update_submitted>
    <last_update_submitted_qc>August 15, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 16, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Istanbul University - Cerrahpasa (IUC)</investigator_affiliation>
      <investigator_full_name>Goksen Kuran Aslan</investigator_full_name>
      <investigator_title>Associate professor</investigator_title>
    </responsible_party>
    <keyword>Interstitial Lung Disease</keyword>
    <keyword>Respiratory Muscles</keyword>
    <keyword>Sleep</keyword>
    <keyword>Quality of Life</keyword>
    <keyword>Fatigue</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lung Diseases</mesh_term>
      <mesh_term>Dyspnea</mesh_term>
      <mesh_term>Lung Diseases, Interstitial</mesh_term>
      <mesh_term>Fatigue</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05993520
  org study id: GAslan-2023
  nct id: NCT05993520
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  Although there are numerous data demonstrating the impact of Interstitial Lung Disease (ILD)
        on respiratory functions, there is a lack of studies investigating the effects of respiratory
        functions on parameters such as sleep quality, dyspnea, and fatigue. The primary objective of
        the study is to examine the influence of changes in respiratory muscle functions in ILD on
        sleep quality, dyspnea, and fatigue parameters. The secondary objective is to investigate the
        effects of respiratory muscle functions in ILD on parameters such as cough, pain, exercise
        capacity, peripheral muscle strength, anxiety, depression, and quality of life.
  Introduction: Despite having numerous data demonstrating the impact of Interstitial Airway
        Disease (IAD) on respiratory functions, there is a lack of studies investigating the effects
        of respiratory functions on parameters such as sleep quality, dyspnea, and fatigue. The
        primary objective of the study is to examine the effects of changes in respiratory muscle
        functions in IAD on sleep quality, dyspnea, and fatigue parameters. The secondary objective
        is to investigate the effects of respiratory muscle functions in IAD on parameters such as
        cough, pain, exercise capacity, peripheral muscle strength, anxiety, depression, and quality
        of life.
  
        Methods: Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who
        were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul
        Faculty of Medicine, and met the inclusion criteria, were included in the project.
        Participants' respiratory function tests, respiratory muscle functions, dyspnea levels,
        cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and
        fatigue levels were evaluated. Pearson Correlation Test was applied to determine the
        relationship between variables. Multiple linear regression analysis was used to examine
        factors that could affect respiratory muscle strength and endurance values.
  observational model: Case-Only
  time perspective: Prospective
  measure: sleep quality-1
  time frame: 5 minutes
  description: Pittsburgh Sleep Quality Index (PSQI) will be used to assess sleep quality. PSQI is a scale consisting of 24 questions that evaluate sleep quality and disturbances in the past month. Each item is scored between 0 and 3, and a total score higher than 5 indicates insufficient sleep quality in the individual.
  measure: Sleep Apnea
  time frame: 5 minutes
  description: Obstructive Sleep Apnea Syndrome Risk: The STOP-BANG questionnaire will be used to assess the risk of Obstructive Sleep Apnea Syndrome (OSAS). The questionnaire consists of a total of eight questions that are answered with "yes" or "no." In the STOP section of the questionnaire, if at least two out of the four questions are answered "yes," it is considered a high risk for OSAS.
  measure: Modified Medical Research Council Questionnaire
  time frame: 5 minutes
  description: To assess dyspnea, the Modified Medical Research Council (mMRC) Questionnaire will be used.
  The mMRC is a scale used to assess the level of dyspnea during daily life activities. It involves a five-point category scale (0 to 4) in which patients choose the expression that best describes their level of dyspnea. As the score increases, the severity of dyspnea also increases.
  measure: Dyspnea-12 Scale
  time frame: 5 minutes
  description: To assess dyspnea, the Dyspnea-12 Scale will be used.
  The Dyspnea-12 Scale is a 12-item questionnaire that measures the intensity of dyspnea. It consists of a four-point Likert-type scale (0=none, 1=mild, 2=moderate, 3=severe) as response options.The minimum score is 0, and the maximum score is 36. An increase in the score indicates an increase in the severity of dyspnea experienced by the patient.
  measure: fatigue
  time frame: 5 minutes
  description: For the assessment of fatigue, the Fatigue Assessment Scale (FAS) will be used. The FAS is a subjective fatigue questionnaire consisting of 10 items. It utilizes a five-point Likert scale (1=Always-5=Never) as response options. The total scores that can be obtained from the FAS range from 10 to 50. Higher scores indicate a higher level of fatigue experienced by the individual.
  measure: Respiratory Function Test
  time frame: 5 minutes
  description: Respiratory Function Test: The respiratory function status of patients will be assessed using spirometric testing.Spirometry is a medical test used to assess the functioning of the lungs. It measures the amount of air a person can inhale and exhale, as well as the speed and volume of airflow. This test is essential for diagnosing and monitoring lung conditions such as interstitial lung disease, chronic obstructive pulmonary disease (COPD), and other respiratory disorders.The spirometry results are compared to predicted values based on factors such as age, height, sex, and ethnicity. This comparison helps healthcare professionals identify any deviations from normal lung function.
  measure: Respiratory Muscle Strength
  time frame: 5 minutes
  description: Respiratory Muscle Strength: The easiest and most common method is measuring mouth pressure during voluntary contraction against a closed airway to open the airway. In the study, respiratory muscle strength will be evaluated using the "Vyaire Medical MicroRPM" device. Maximum Inspiratory Pressure (MIP): At least three measurements are taken, and the highest value is recorded. Maximum Expiratory Pressure (MEP): The best of at least three measurements is recorded.
  measure: Comorbidity
  time frame: 3 minutes
  description: Charlson Comorbidity Index: It is a widely used index in clinical practice that queries chronic systemic diseases, assesses their frequency and relationships. It consists of nineteen different items. The scores obtained from the patient's comorbid conditions are added together to obtain a score, and a score is also added based on the patient's age. This age score is 1 for ages 50-59, 2 for ages 60-69, 3 for ages 70-79, 4 for ages 80-89, and 5 for ages 90-99.
  measure: Respiratory Muscle Endurance:
  time frame: 8 minutes
  description: Respiratory Muscle Endurance: In respiratory muscle endurance measurement, an incremental threshold load test will be applied using the "Threshold IMT" device. According to the incremental threshold load protocol, after determining the MIP value, the threshold pressure is set at approximately 20-40% of MIP. The threshold pressure is increased every two minutes. The highest pressure that the patient can sustain for at least one minute is recorded as the patient's respiratory muscle endurance value.
  measure: Cough
  time frame: 5 minutes
  description: Leicester Cough Questionnaire will be used for the assessment of cough. It consists of 19 items with a 7 point likert response scale (range from 1 to 7).Each item is developed to assess symptoms during cough and impact of cough on three main domains: physical, psychological and social. Scores are calculated as a mean of each domain and the total score is calculated by adding every domain score. The total severity score ranges 3-21, with a lower score indicating greater impairment of health status due to cough.
  measure: Symptoms Seveerity
  time frame: 1 minutes
  description: Dispnea, Pain, and Cough Severity: Dispnea, pain, and cough severity will be assessed using the Visual Analog Scale (VAS). VAS is used to convert some values that cannot be measured numerically into numerical form. It involves a 100 mm line with the two endpoints representing the two extreme definitions of the parameter to be evaluated (e.g., no pain/cough - very severe pain/cough). The patient is asked to indicate their own condition by drawing a line, placing a dot, or marking a point on this line to indicate where their situation corresponds. The point marked by the patient is measured using a ruler. The resulting number represents the patient's level of pain/cough severity.
  measure: exercise capacity
  time frame: 8 minutes
  description: The Six-Minute Walk Test (6MWT) will be used to assess exercise capacity. The 6MWT determines individuals' submaximal functional exercise capacity. The patient will be asked to walk as far as possible at their own walking pace for six minutes in a straight 30-meter corridor. Before starting the test, the patient rests in a sitting position in the corridor for 10 minutes. Prior to the test, oxygen saturation, heart rate, blood pressure, dyspnea, and leg fatigue scores are recorded using the Modified Borg Scale. If the patient wants to rest during the test, the resting time is included in the test duration without stopping the stopwatch. At the end of the test, the assessments made before the test are repeated. The distance walked in six minutes (6MWD) is recorded in meters.
  measure: peripheral muscle strength
  time frame: 5 minutes
  description: The "J-Tech CommanderTM Muscle Tester" hand-held dynamometer will be used to assess the strength of the quadriceps femoris muscle. The hand-held dynamometer is a simple, easy-to-use, portable, time-efficient, inexpensive, and lightweight device that measures maximum isometric muscle strength.
  measure: anxiety&depression
  time frame: 5 minutes
  description: The Hospital Anxiety and Depression Scale (HADS) will be used to determine the anxiety and depression status. HADS is a self-report questionnaire developed to assess the risk, level, and severity of anxiety and depression in individuals with physical illnesses and those seeking primary healthcare services. It consists of a total of 14 questions, with seven questions (odd numbers) measuring anxiety and the other seven questions (even numbers) measuring depression. It is a four-point Likert-type scale. The cutoff score for the anxiety subscale (HADS-A) is 10/11, and for the depression subscale (HADS-D) is 7/8.
  measure: health problems
  time frame: 5 minutes
  description: The Nottingham Health Profile (NHP) was originally created as a standardised tool to survey health problems and measure medical or social interventions. The NHP is a patient-reported questionnaire. Respondents tick yes or no boxes to answer questions about their health and its effects on their daily life.
  The questionnaire is divided into two parts. The first parts comprises 38 questions in six categories: sleep, physical mobility, energy, pain, emotional reactions, and social isolation. This first section is weighted to reflect how severe an impact the respondent thinks their health is having on the above areas of life. The second part of the NHP is made up of seven statements about areas of life that are commonly affected by health: paid employment, jobs around the house, social life, personal relationships, sex life, hobbies and interests, and holidays. Scores on the NHP can range from 0 i.e. no distress to 100 i.e severe distress.
  arm group label: Interstitial Lung Disease
  description: Between June 2020 and June 2023, a total of 36 voluntary participants, aged 18 and above, who were receiving treatment at the Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, and met the inclusion criteria, were included in the study.
  intervention type: Other
  intervention name: Assessment
  description: Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
  arm group label: Interstitial Lung Disease
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 70 Years
  facility: 
  country: Turkey
  citation: Bloem AEM, Houben-Wilke S, Mostard RLM, Stoot N, Janssen DJA, Franssen FME, Custers JWH, Spruit MA. Respiratory and non-respiratory symptoms in patients with IPF or sarcoidosis and controls. Heart Lung. 2023 Sep-Oct;61:136-146. doi: 10.1016/j.hrtlng.2023.05.013. Epub 2023 Jun 2.
  PMID: 37269615
  responsible party type: Principal Investigator
  investigator affiliation: Istanbul University - Cerrahpasa (IUC)
  investigator full name: Goksen Kuran Aslan
  investigator title: Associate professor
  mesh term: Lung Diseases
  mesh term: Dyspnea
  mesh term: Lung Diseases, Interstitial
  mesh term: Fatigue
  sharing ipd: No